Matrix For Drug Release Research Articles

Profile of a Composite Based on Bacterial Cellulose and Polyvinyl Alcohol as a Drug Release Matrix for Tetracycline Hydrochloride

Bacterial cellulose (BC) is a natural polymer with good mechanical properties and hydrophilicity. Polyvinyl alcohol (PVA) is a synthetic polymer widely used in medicine. Both have been researched for their potential in drug release and acceptance. This study aims to determine the role of BC and PVA as drug release matrices for tetracycline hydrochloride (TCH), with additional fillers such as graphite (G) and TiO2. The results showed that the composites with BC matrix had lower mechanical properties than those with PVA matrix, with tensile strength values of 6.4075 and 17.446 MPa, respectively. However, the BC matrix was superior in porosity and swelling ability. The drug release testing of TCH from the composites showed that the appropriate model to describe drug release in BC matrix composites was in zero order, while the PVA matrix was in first order. The antibacterial activity of the composites on both matrices was tested against Staphylococcus aureus. The results indicate that both composites have potential applications in promising biomedical fields.

Combination of Chemical and Physical Cancer Therapeutics Developed with Microcapsules Made of κ-Casein and Gold Nanoparticles in the Presence of Drug-Loaded Phase Change Materials.

Tumor heterogeneity requires development of an anticancer system equipped with both chemical and physical therapeutics to eradicate cancer exhibiting drug resistance and clonal evolution into diverse tumor cells. Assortment of various toxic components into one platform without compromising their individual toxic activity remains a formidable task. Herein, a novel drug delivery system (DDS) exerting potent cytotoxicity toward cancer cells was fabricated with gold nanoparticles (AuNPs) coated with an innocuous self-assembly protein of κ-casein (κC). Pickering emulsions of the κC-AuNP conjugates in the presence of chloroform inside led to the κC-AuNP microcapsules being stabilized via robust β-sheet formation between κC molecules located on the single-layered shell made of κC-AuNPs. Phase change material (PCM) comprising a eutectic mixture of lauric acid and myristic acid with the melting point of 43 °C was encapsulated in the presence of a hydrophilic anticancer drug of doxorubicin (Dox), in which the PCM has played multiple functions such as drug-holding matrix and thermoresponsive gating material for drug release. Once liberated with the heat generated by the AuNPs upon a near-infrared (NIR) irradiation at 808 nm, the PCM by itself exhibited not only chemical cytotoxicity but also physical toxic effects such as membrane destabilization of the cells and a possible cellular fixative effect toward cancer cells by the solidified PCM at body temperature. Moreover, the PCM was shown to facilitate the intranuclear localization of Dox. As a result, the DDS comprising κC-AuNP microcapsules containing Dox-loaded PCM was demonstrated to show a powerful anticancer effect upon the NIR irradiation, which unleashed several toxic agents such as Dox, PCM, heat-generating AuNPs, and tissue-immobilizing solidified PCM. Therefore, the κC-AuNP microcapsules would serve as an anticancer system into which diverse chemical and physical therapeutic agents could be combined to effectively remove the heterogeneous and drug resistant cancer cells.

AN OVERVIEW ON CUBOSOMES AS REMARKABLE NANOCARRIER FOR DRUG DELIVERY

Lipids have been extensively used as main ingredients in various drug delivery systems, such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers and lipid-based lyotropic liquid crystals. Over the past few years, lipid-based lyotropic, bicontinuous cubic phase liquid crystals have been investigated for their applicability to controlled delivery of active ingredients. Lipid-based lyotropic liquid crystals have highly ordered, thermodynamically stable internal nanostructure, thereby offering the potential as a sustained drug release matrix. The emulsification of cubic lipid phases in water results in the production of cubosomes that can be defined as nanoparticulate disperse systems characterised by high biocompatibility and bioadhesivity. The unique microstructure of cubosomes have the potentials to control the release of active ingredients, improve drug bioavailability and reduce toxicity, enhance the stability of drugs and to increase the penetrability of drug after topical application. This reflection will provide an overview of the lipids used to prepare cubic phase at physiological temperature, as well as the influencing factors on the phase transition of liquid crystals. In particular, the most current research progresses on cubic phase as drug delivery systems and its applications will be discussed. It might act as smart lipid nanoparticles for drug delivery.

Biodegradable double-network GelMA-ACNM hydrogel microneedles for transdermal drug delivery.

As a minimally invasive drug delivery platform, microneedles (MNs) overcome many drawbacks of the conventional transdermal drug delivery systems, therefore are favorable in biomedical applications. Microneedles with a combined burst and sustained release profile and maintained therapeutic molecular bioactivity could further broaden its applications as therapeutics. Here, we developed a double-network microneedles (DN MNs) based on gelatin methacrylate and acellular neural matrix (GelMA-ACNM). ACNM could function as an early drug release matrix, whereas the addition of GelMA facilitates sustained drug release. In particular, the double-network microneedles comprising GelMA-ACNM hydrogel has distinctive biological features in maintaining drug activity to meet the needs of application in treating different diseases. In this study, we prepared the double-network microneedles and evaluated its morphology, mechanical properties, drug release properties and biocompatibility, which shows great potential for delivery of therapeutic molecules that needs different release profiles in transdermal treatment.

Cytocompatibility of oleic acid modified iron oxide nanoparticles

Our long-term goal is to utilize oleic acid-modified iron oxide (OA-Fe3O4) nanoparticles embedded into a monoglyceride matrix for remote drug release utilizing an alternating magnetic field (AMF). However, the toxicological behavior of OA-Fe3O4 nanoparticles when in contact with biological tissues remains unknown. The size, shape, and surface morphology of OA-Fe3O4 nanoparticles prepared in our laboratory were evaluated using SEM and TEM. These data show that the OA-Fe3O4 nanoparticle preparations do not form aggregates and maintain the expected size and shape. We also used HTB-19, a human mammary tumor cell line, to assay the cytocompatibility of OA-Fe3O4 nanoparticles of different sizes (5, 10, 20, and 30 nm) at varying doses (6.25, 12.5, 25, and 50 µg/mL) using CytoTox-Glo™ cytotoxicity kit and phase-contrast inverted microscopy. These results indicate that there is no appreciable cytotoxicity at the lowest (6.25 µg/mL) concentration. Even the highest (50 µg/mL) concentration used in our study show > 75% cell viability. Microscopic morphological assessment performed using phase-contrast inverted microscopy revealed internalization of the nanoparticles and proliferation of cells in the presence of the OA-Fe3O4 nanoparticles. Taken together, our results show that OA-Fe3O4 nanoparticles are a safe and promising biocompatible excipient for drug delivery.

3D Printed Mini-Floating-Polypill for Parkinson's Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy.

Therapy for Parkinson’s disease is quite challenging. Numerous drugs are available for symptomatic treatment, and levodopa (LD), in combination with a dopa decarboxylase inhibitor (e.g., benserazide (BZ)), has been the drug of choice for years. As the disease progresses, therapy must be supplemented with a dopamine agonist (e.g., pramipexole (PDM)). Side effects increase, as do the required dose and dosing intervals. For these specific requirements of drug therapy, the 3D printing method fused deposition modelling (FDM) was applied in this study for personalized therapy. Hot melt extrusion was utilized to produce two different compositions into filaments: PDM and polyvinyl alcohol for rapid drug release and a fixed combination of LD/BZ (4:1) in an ethylene-vinyl acetate copolymer matrix for prolonged drug release. Since LD is absorbed in the upper gastrointestinal tract, a formulation that floats in gastric fluid was desired to prolong API absorption. Using the FDM 3D printing process, different polypill geometries were printed from both filaments, with variable dosages. Dosage forms with 15–180 mg LD could be printed, showing similar release rates (f2 > 50). In addition, a mini drug delivery dosage form was printed that released 75% LD/BZ within 750 min and could be used as a gastric retentive drug delivery system due to the floating properties of the composition. The floating mini-polypill was designed to accommodate patients’ swallowing difficulties and to allow for individualized dosing with an API release over a longer period of time.

RADIATION SYNTHESIS OF POLY(VINYL ALCOHOL) PVA–(POLYVINYL PYRROLIDONE) PVP FOR IMMOBILIZATION OF CAPTOPRIL

RADIATION SYNTHESIS OF PVA POLY(VINYL ALCOHOL)–PVP (POLYVINYLPYRROLIDONE) for IMMOBILIZATION OF CAPTOPRIL. The aim of this work is to prepare Polyvinyl alcohol (PVA)- Polyvinylpyrrolidone (PVP) hydrogel with varying irradiation doses and drug dose to be used as a matrix for immobilization and control drug release of captopril. Immobilization and release of captopril in PVA-PVP hydrogel copolymer have been carried out. A mixture of PVA-PVP (6:4 w/w) solution containing captopril (10-20 mg), freeze-thawing, irradiated using gamma rays at various irradiation doses (0-20 kGy). The gel fraction and water absorption were determined gravimetrically. The pores structure of hydrogels were observed using SEM (Scanning Electron Microscope). The captopril released from hydrogel in NaCl 0.9% solution was measured using a UV-Vis spectrophotometer. After evaluated, it was found that with increasing dose up to 20 kGy, the gel fraction increases, and water absorption decreases, and the cumulative drug released decreases. SEM measurement showed that hydrogel had heterogeneous pores. PVA-PVP hydrogel prepared using gamma rays can be considered as a matrix for drug release.

Design of circular-ring film embedded contact lens for improved compatibility and sustained ocular drug delivery

Contact lenses are ideal medical devices to sustain the release of ophthalmic drugs. However, the incorporation of drug loaded system can cause visual obstruction and poor oxygen/light permeability which restrict the application of contact lens for long-term wearing. Inspired by the physiological structure of our human eyes, we assume a circular-ring type inner layer embedded CLs might be a good solution to address the above-mentioned problems. In this study, taking betaxolol hydrochloride (BH) as a model drug, its complex with ion exchange resin was used as a carrier for adjusting drug loading amount, which is being dispersed into circular-ring shape Eudragit® S100 film as an inner layer, silicone-based hydrogel as the outer layer. Influence of resin particle size and drug/S100 ratio on drug release profiles was investigated. It was demonstrated that using resin as a carrier can not only increase drug loading amount but also sustain drug release, with the drug release rate well-tuned by either changing particle size of the resin or S100 ratio. Meanwhile S100 can well function as a pH-triggered drug release matrix, with limited drug leakage in the storage medium. Light transmittance of over 97% was achieved in the novel circular-ring layer-embedded CLs. Oxygen permeability coefficient (Dk) of the circular-ring film embedded CLs was 31.1 ± 3.7 barrer, similar to that of pure CLs. The sustained drug release behavior of this circular-ring embedded CLs was also well demonstrated in vivo. A level A IVIVC between in vitro drug release and in vivo drug concentration in tear fluid of the circular-ring embedded CLs was established. In conclusion, this circular-ring embedded contact lens is very promising for ophthalmic drug delivery with enhanced compatibility, sustained and pH triggered drug release characteristics.

Hyaluronic Acid and Controlled Release: A Review.

Hyaluronic acid (HA) also known as hyaluronan, is a natural polysaccharide—an anionic, non-sulfated glycosaminoglycan—commonly found in our bodies. It occurs in the highest concentrations in the eyes and joints. Today HA is used during certain eye surgeries and in the treatment of dry eye disease. It is a remarkable natural lubricant that can be injected into the knee for patients with knee osteoarthritis. HA has also excellent gelling properties due to its capability to bind water very quickly. As such, it is one the most attractive controlled drug release matrices and as such, it is frequently used in various biomedical applications. Due to its reactivity, HA can be cross-linked or conjugated with assorted bio-macromolecules and it can effectively encapsulate several different types of drugs, even at nanoscale. Moreover, the physiological significance of the interactions between HA and its main membrane receptor, CD44 (a cell-surface glycoprotein that modulates cell–cell interactions, cell adhesion and migration), in pathological processes, e.g., cancer, is well recognized and this has resulted in an extensive amount of studies on cancer drug delivery and tumor targeting. HA acts as a therapeutic but also as a tunable matrix for drug release. Thus, this review focuses on controlled or sustained drug release systems assembled from HA and its derivatives. More specifically, recent advances in controlled release of proteins, antiseptics, antibiotics and cancer targeting drugs from HA and its derivatives were reviewed. It was shown that controlled release from HA has many benefits such as optimum drug concentration maintenance, enhanced therapeutic effects, improved efficiency of treatment with less drug, very low or insignificant toxicity and prolonged in vivo release rates.

Sustained release from biodegradable metallic matrix—The entrapment of drugs within iron

Iron and its alloys have been widely used for variety of medical implants. These are used for long term applications as cheap implants with high inertness and low corrosion rate, and also as implants with high biocompatibility (the fourth-generation type). Such degrading implants can provide a temporary scaffold while the body heals. In addition to the needed mechanical support, it is highly desirable to provide local drug therapy, providing antibacterial properties, preventing rejection of the implant, and more. So far, the combination of a degradable metallic implant which serves also as a three-dimensional matrix for drug release, remained un-answered. Here we present, we believe for the first time realization of this concept: Entrapment of drugs within a 3D degradable metal matrix—iron—from which the entrapped drugs are sustain-released. This new type of material is based on the molecular metals entrapment materials methodology, resulting in drugs@Fe. Two drugs have been successfully entrapped and released: chlorhexidine - an antiseptic drug, and rapamycin—used for avoiding transplant rejection. The delivery profiles of the composites were studied in two forms—powders and pressed discs showing two different types of drug release profiles. The release of the drugs from the powder hasa first order release profile, while the pressed disk is a slower, zero-order release profile, which is highly desirable due to the constant rate of the release. Full characterization of the metallic biomaterials is provided, including XRD, SEM, TGA, elemental analysis, and surface area/porosity analysis.

Development of 3D Printed Tablets by Fused Deposition Modeling Using Polyvinyl Alcohol as Polymeric Matrix for Rapid Drug Release

In this study, the processability of polyvinyl alcohol (PVA), a water-soluble polymer, into melt-extruded filaments and then into 3D printed tablets by fused deposition modeling was studied. PVA is semicrystalline with Tg and m.p. of ~45°C and ~190°C, respectively. After screening several plasticizers, sorbitol was selected to enhance melt extrudability of PVA. Carvedilol and haloperidol, 2 basic compounds with pH-dependent solubility, were used as model drugs. Miscibility of the drugs with PVA, with and without added sorbitol as plasticizer, was also tested to determine whether any amorphous solid dispersion was formed that would facilitate rapid and pH-independent dissolution. Finally, the drug release from physical mixtures, crushed extrudates, and printed tablets were determined. Owing to high m.p. and high melt viscosity of PVA, filaments containing 10% and 20% drug required 180°C-190°C for extrusion, which could be reduced to ~150°C by adding 10% sorbitol. The printing temperature of 210°C was, however, required. Miscibility of carvedilol and haloperidol with PVA were, respectively, ~20% and <10%. PVA provided complete drug release from 3D printed tablets with 10% and 20% carvedilol and 60% infill in ~45 min at both pH 2 and 6.8. However, despite relatively rapid dissolution rate, high processing temperature and limited drug-polymer miscibility could be potential development issues with PVA.

Phosphodiester Hydrogels for Cell Scaffolding and Drug Release Applications.

Given the major structural role phosphodiesters play in the organism it is surprising they have not been more widely adopted as a building block in sophisticated biomimetic hydrogels and other biomaterials. The potential benefits are substantial: phosphoester-based materials show excellent compatibility with blood, cells, and a remarkable resistance to protein adsorption that may trigger a foreign-body response. In this work, a novel class of phosphodiester-based ionic hydrogels is presented which are crosslinked via a phosphodiester moiety. The material shows good compatibility with blood, supports the growth and proliferation of tissue and presents opportunities for use as a drug release matrix as shown with fluorescent model compounds. The final gel is produced via base-induced elimination from a phosphotriester precursor, which is made by the free-radical polymerization of a phosphotriester crosslinker. This crosslinker is easily synthesized via multigram one-pot procedures out of common laboratory chemicals. Via the addition of various comonomers the properties of the final gel may be tuned leading to a wide range of novel applications for this exciting class of materials.

Comparing the release of erythromycin and vancomycin from calcium polyphosphate hydrogel using different drug loading methods.

Calcium polyphosphate (CPP) hydrogel is used to load erythromycin (EM) and vancomycin (VCM) by means of two loading methods: they are either added directly to the formed CPP hydrogel (Gel Mixture method) or mixed with CPP powders, followed by the formation of CPP-antibiotic hydrogel (Powder Mixture method). The release of loaded antibiotics from CPP hydrogel is measured up to 48 hr. Compared to Powder Mixture method, Gel Mixture method significantly reduced the burst release of embedded antibiotics. A significant change in CPP hydrogel Raman characteristic peaks is observed only in Gel Mixture method, indicating a close interaction between embedded antibiotics with CPP hydrogel matrix. In contrast, a similarity between characteristic peaks of CPP hydrogel and Powder Mixture method shows that antibiotic incorporation does not interfere with CPP gel formation, resulting in no ionic interaction between antibiotic and polyphosphate chains. Rheometer analysis further confirms that the hydrophobic nature of EM impacts the viscoelastic properties of CPP hydrogel, whereas the hydrophilic VCM exhibits a higher loading efficiency. The potential application of CPP hydrogel as a ceramic matrix for sustained drug release warrants further investigation.

PVP/Clay/Vanadium Oxide Nanocomposites Development and Characterization for Potential Use as Controlled Drug Release Matrix in Diabetes’ Treatment

Research in drug release field, nowadays, focuses on more efficient systems for better release of the drug and wider timespan of action, granting several benefits to the patient’s organism and to the industry. The present work aims on developing a matrix of polymer nanocomposite based on Polyvinylpyrrolidone (PVP), bentonite clay and two different vanadium oxides, via spray drying technique. The goal is to achieve a long and steady release of metformin hydrochloride in future formulations with this drug. Since either the nanocomposites or metformin hydrochloride is highly hydrophilic, it is most suited for a future formulation of tablets. For now, the nanocomposites obtained were characterized through Nuclear Magnetic Resonance (NMR), Scanning Electron Microscopy (SEM), X-Ray Diffraction (XRD), Thermogravimetric Analysis (TGA) and Fourier Transform Infrared Spectroscopy (FTIR). The SEM and XRD analysis portrayed a very amorphous and homogenized material. TGA and FTIR proved the insertion of the nanoparticles, thus granting to the new material a slightly higher thermal resistance. The NMR analysis, using T1H parameters, is key for determining the formulations would behave better for extending the resistance of the nanocomposite’s matrix with the drug in later dissolution of tablets.

Physicochemical characterization and thermal behavior of hexosomes containing ketoconazole as potential topical antifungal delivery system

Objective: The main purpose of this article is to show the valuable characteristics that liotropic liquid crystal systems possess to be employed as new drug delivery systems.Significance: Colloidal aqueous dispersions of lyotropic liquid crystal mesophases such as the identified as cubosomes and hexosomes, and so on, have received considerable attention due to their unique nanostructures and their thermodynamic properties, which provide the potential as a sustained drug release matrix. Additionally, their large surface area and similarity with the liquid crystal structures of intercellular lipids of stratum corneum enhances the interaction with the skin and mucous, increasing the potential for topical drug delivery efficiency of biopharmaceutical class II drugs as the antifungal ketoconazole.Methods: This article presents the results in morphological characteristics, particle size, ζ potential, flow, thermal behavior and drug release studies of hexosomes containing ketoconazole (LHLC-K) obtained with glycerol monooleate, propylene glycol monolaurate, poloxamer, and water mixtures.Results: This colloidal system exhibits a Newtonian-type flow and a hexagonal nanostructure with a median particle size of 107 ± 20 nm and ζ potential of +4.45 ± 0.50 mV. Through differential scanning calorimetry studies, the LHLC-K demonstrated physical and chemical stability for more than six months and mesophasic thermal reversibility between 10 and 50 °C. Finally, LHLC-K releases ketoconazole following a kinetics described by the first order model.Conclusions: Physicochemical properties of the hexosomes containing ketoconazole are important for topical mycosis treatment administration, conditions of storage, and for its incorporation into the formulation of semi-solid dosage forms.

In vitro bioactivity and cytotoxicity of films based on mesocarp of Orbignya sp. and carboxymethylcellulose as a tannic acid release matrix

This study aims to obtain mesocarp films of Orbignya sp. (MB) and carboxymethylcellulose (CMC) for application as a drug release matrix. Tannic acid (TA) was used as a standard drug. The films were evaluated by infrared, swelling power, TA release profile, bioactivity and in vitro cytotoxicity. Infrared results indicated absorption at 1.205 cm−1, which is characteristic of ester group from the incorporated tannin. The MB-CMC film had 449.15% swelling power, release of 71.01% of TA of the matrix after 24 h. Films showed scavenger activity of radicals DPPH (79.07 ± 1.71% to 82.17 ± 1.94%) and ABTS+ (82.20 ± 0.30% to 88.90 ± 1.05). The MB-CMC film also showed in vitro cytotoxicity on sarcoma-180 (91.86 ± 9.97%) and on promastigote forms of Leishmania major (100%). Polymers showed good compatibility in the mixture and the results suggest the films obtained are promising as drug release matrices.

Biocompatible waterborne polyurethane-urea elastomer as intelligent anticancer drug release matrix: A sustained drug release study

Waterborne biodegradable polyurethane–urea (WPUU) elastomer is a revolutionary step in the field of green polymer chemistry. In the present study, emulsifier–free biodegradable WPUU elastomer was synthesized by using lysine as an internal emulsifier as well as a chain extender. WPUU elastomer was used as the stimuli–responsive drug release matrix, loaded by cisplatin as a model anticancer drug. Sustained drug release was studied by changing pH (4.4–7.4), drug release medium, and NCO/OH ratio (3–4). Furthermore, significantly inhibitory effect against Sw–620 cancer lines was observed. Highest cumulative drug release of 71.9% was observed at pH of 7.4 in phosphate buffer saline (PBS) by the system having NCO/OH=3 for 250h. The oxidative degradation was evaluated in CoCl2/H2O2 solution. Mechanical properties were tested by using the mechanical testing machine. The synthesized WPUU films exhibited high thermal stability, hardness, tensile strength and hydrophobicity.

Application of a Biodegradable Polyesteramide Derived from L-Alanine as Novel Excipient for Controlled Release Matrix Tablets.

This pre-formulation study assays the capacity of the polyesteramide PADAS, poly (L-alanine-dodecanediol-L-alanine-sebacic), as an insoluble tablet excipient matrix for prolonged drug release. The flow properties of PADAS were suitable for tableting, and the compressibility of tablets containing exclusively PADAS was evaluated by ESEM observation of the microstructure. The tablets were resistant to crushing and non-friable and they did not undergo disintegration (typical features of an inert matrix). Tablets containing 33.33% sodium diclofenac (DF), ketoprofen (K) or dexketoprofen trometamol (DK-T) as a model drug, in addition with 66.67% of polymer, were formulated, and the absence of interactions between the components was confirmed by differential scanning calorimetry. Dissolution tests showed that PADAS retained DF and K and prolonged drug release, following a Higuchi kinetic. The tablets containing DK-T did not retain the drug sufficiently for prolonged release to be established. Tablets containing DK-T and 66.67, 83.33 or 91.67% PADAS, compressed at 44.48 or 88.96kN, were elaborated to determine the influence of the polymer amount and of the compression force on DK-T release. Both parameters significantly delayed drug release, except when the proportion of polymer was 91.67%.

Formulation and Optimization of Controlled Release 5-Fluorouracil Tablets for Colonic Delivery

: Objective: Formulations were developed for targeted controlled delivery of 5-fluorouracil at the colonic site. Methods: Probable dose for drug loading in the tablets and duration of drug release at the colon was determined. Core tablets were formulated with an aim to deliver the drug at a constant rate following zero order kinetics throughout the duration of release. Hydroxypropyl methylcellulose E15 and potassium chloride were incorporated as hydrophilic agents in the core matrix for drug release at the desired level and the formulation with the best release profile was chosen for coating with a coating solution containing Eudragit S100, polyethylene glycol 400 and talc. The amounts of Eudragit S100 and weight gain of the tablet were optimized using sequential simplex optimization method. Results: The optimized coated formulation (0.6875 g of Eudragit S100; 7.5% weight gain) was able to provide minimum drug release in the 5 hr lag time (5.9% of cumulative release) and an average release rate of 19.8% per hr thereafter. Conclusion: The optimized formulation for 5-Fluorouracil delivery at the colonic site was able to achieve a sufficient lag time and controlled drug release and can be highly beneficial for optimum therapeutic activity and negligible side effects when administered orally.Key words: Colonic delivery, Eudragit S100, Hydroxypropyl methylcellulose E15, Potassium chloride, Sequential optimization, Zero order release.

Spotlight on Biomimetic Systems Based on Lyotropic Liquid Crystal.

The behavior of lyotropic biomimetic systems in drug delivery was reviewed. These behaviors are influenced by drug properties, the initial water content, type of lyotropic liquid crystals (LLC), swell ability, drug loading rate, the presence of ions with higher or less kosmotropic or chaotropic force, and the electrostatic interaction between the drug and the lipid bilayers. The in vivo interaction between LCC—drugs, and the impact on the bioavailability of drugs, was reviewed. The LLC with a different architecture can be formed by the self-assembly of lipids in aqueous medium, and can be tuned by the structures and physical properties of the emulsion. These LLC lamellar phase, cubic phase, and hexagonal phase, possess fascinating viscoelastic properties, which make them useful as a dispersion technology, and a highly ordered, thermodynamically stable internal nanostructure, thereby offering the potential as a sustained drug release matrix for drug delivery. In addition, the biodegradable and biocompatible nature of lipids demonstrates a minimum toxicity and thus, they are used for various routes of administration. This review is not intended to provide a comprehensive overview, but focuses on the advantages over non modified conventional materials and LLC biomimetic properties.